• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHAO Xiaohui,LI Wenwei,LI Yucui,LIU Zhirong,XIE Nan,MA Xiao.Research progress on the toxicology, processing methods and quality control of aconite[J].Journal Of Pharmaceutical Research,2026,45(4):458-463,475[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2165times   Download 1343次 QR Code for this article
Scan with your phone!
附子的毒理学、炮制方法及质量控制方法研究进展
张晓惠,李文伟,李玉璀,刘志荣,谢楠,马潇
Font:Larger+|Default|Smaller-
(甘肃省药品检验研究院,甘肃省中藏药检验检测技术工程实验室,国家药品监督管理局中药材及饮片质量控制重点实验室,甘肃 兰州 730070)
摘要:
附子作为传统中药,其药理活性与毒性均源于生物碱类成分,尤其是双酯型生物碱,可通过干扰离子通道引发心脏、神经及肝肾毒性。为降低毒性风险,临床上通常采用炮制品入药,通过炮制工艺将双酯型生物碱转化为毒性较低的单酯型和醇胺型生物碱,实现减毒增效的目的。同时,建立科学的质量控制体系是保障临床用药安全的重要措施。本文从毒理学机制、炮制方法和质量控制三个方面综述附子研究的最新进展,以期为相关研究提供参考依据。
关键词:  附子  毒理学  炮制方法  质量控制方法
DOI:10.13506/j.cnki.jpr.2026.04.014
基金项目:国家药品监督管理局中药材及饮片质量控制重点实验室项目(No.2024GSMPA-KL19)
Received Date:July 25, 2025   Revision Date:October 23, 2025   Publication Date:April 30, 2026
Research progress on the toxicology, processing methods and quality control of aconite
ZHAO Xiaohui,LI Wenwei,LI Yucui,LIU Zhirong,XIE Nan,MA Xiao
(Gansu Engineering Lab for Traditional Chinese Medicine,National Medical Products Administration Key Laboratory for Quality Control of Traditional Chinese Medicines and Decoction Pieces,Gansu Institute for Drug Control,Lanzhou 730070,China)
Abstract:
As a traditional Chinese medicine, Aconite exhibits both pharmacological activities and toxicity due to its alkaloid constituents, particularly diester-diterpenoid alkaloids(DDAs). These DDAs can induce cardiotoxicity, neurotoxicity, and hepatorenal toxicity by interfering with ion channels. To mitigate toxicity risks, processed Fuzi is commonly used in clinical practice, where DDAs are converted into less toxic monoester-diterpenoid alkaloids and lipo-alkaloids through processing techniques, achieving both toxicity reduction and efficacy enhancement. Furthermore, establishing a scientific quality control system is crucial for ensuring clinical safety. This review summarizes recent advances in three key aspects: toxicological mechanisms, processing methods, and quality control, aiming to provide valuable references for future research.
Key words:  Aconite  Toxicology  Processing methods  Quality control methods
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.